Cycle on Aug 31, 2026

I will list the open threads and watches for this topic to understand what active investigations or catalysts are currently being tracked.

I will fetch the market views for the core public managed care companies to look at their latest financial stats, multiples, margins, and recent news. I will start with UnitedHealth Group (UNH), Elevance Health (ELV), and Cigna Group (CI).

I will also fetch the market views for Cigna (CI), CVS Health (CVS), Humana (HUM), Centene (CNC), and Elevance Health (ELV) to get a complete picture of the sector's financial metrics. Let's do this in batches or one by one. Let's get CVS, HUM, and ELV.

I will now fetch the market views for Humana (HUM), Elevance Health (ELV), Cigna (CI), and Centene (CNC). Let's fetch HUM first.

Now let's fetch Elevance Health (ELV), Cigna (CI), and Centene (CNC). Let's fetch ELV.

Let's fetch Cigna (CI) and Centene (CNC). Let's fetch CI.

Let's fetch Centene (CNC) as well.

Let's do some web searches to find recent articles, SEC filings, or earnings call transcripts from Q2 2026 (or late 2025/2026) discussing: 1. UNH/Optum segment margins, MLR (medical loss ratio), and how much profit comes from Optum vs. UnitedHealthcare. 2. CVS/Aetna's margin pressure (particularly in Medicare Advantage) and CVS Caremark (PBM) profit contribution. 3. Cigna's Evernorth (PBM + specialty pharmacy) vs. Cigna Healthcare (insurance) segment margins. 4. Humana's Medicare Advantage margin recovery, Star ratings litigation, and CenterWell (vertical integration). 5. Centene's Medicaid and ACA Marketplace margins. 6. Any recent FTC/DOJ actions on PBMs or vertical integration. Let's do a search on: `UnitedHealth Q2 2026 earnings transcript Optum UnitedHealthcare segment profit` or similar. Since we are in late August 2026, Q2 2026 has just been reported (June 30, 2026 quarter). Let's search for recent articles on how these companies make money. Let's do a broad search first.

Let's examine the Stocktitan SEC filing link for UnitedHealth Group's Q2 2026 10-Q. I'll fetch that URL to see the exact numbers for Q2 2026 vs Q2 2025. It has table structures containing segment revenues and operating earnings for UnitedHealthcare and Optum. Let's do a `web_fetch` on `https://www.stocktitan.net/sec-filings/UNH/10-q-unitedhealth-group-inc-quarterly-earnings-report-b2c1fe97d046.html`. This will give us the exact numbers from the Q2 2026 10-Q.

This is extremely valuable. The Q2 2026 10-Q filing contains detailed segment numbers for UnitedHealth Group (UNH). Let's review the key figures for the three months ended June 30, 2026: - UnitedHealthcare Segment: - Revenues: $86.017 billion (down slightly from $86.103 billion in Q2 2025). - Operating earnings (Earnings from operations): $3.942 billion (up nearly 90% from $2.075 billion in Q2 2025). - Operating margin: 4.6% (up from 2.4% in Q2 2025). - Optum Segment (Consolidated): - Revenues: $65.663 billion (down from $67.225 billion in Q2 2025). - Operating earnings: $4.049 billion (up 32% from $3.075 billion in Q2 2025). - Operating margin: 6.2% (up from 4.6% in Q2 2025). - Optum Health Segment: - Revenues: $23.472 billion (down from $24.725 billion in Q2 2025). - Operating earnings: $1.190 billion (up 177% from $429 million in Q2 2025). - Operating margin: 5.1% (up from 1.7% in Q2 2025). - Optum Insight Segment: - Revenues: $5.402 billion (up from $5.232 billion in Q2 2025). - Operating earnings: $1.369 billion (up 14% from $1.205 billion in Q2 2025). - Operating margin: 25.3% (up from 23.0% in Q2 2025). - Optum Rx Segment: - Revenues: $38.292 billion (down slightly from $38.459 billion in Q2 2025). - Operating earnings: $1.490 billion (up 3% from $1.441 billion in Q2 2025). - Operating margin: 3.9% (up from 3.7% in Q2 2025). Let's look at the medical care ratio (MCR) for Q2 2026: - Consolidate MCR is 86.7% for Q2 2026, down from 89.4% in Q2 2025. - The 10-Q notes: "Membership declined, with UnitedHealthcare medical enrollment down to 48.5 million, including 9% reductions in Medicare Advantage and Medicaid lives, reflecting funding pressures, pricing and benefit actions, and state eligibility changes." - Also: "Optum Health revenues fell 5% on fewer value‑based care patients, though segment earnings increased on cost management and reserve releases." Let's check Cigna's Q2 2026 segment performance, specifically looking at Evernorth (PBM + specialty) vs Cigna Healthcare (insurance). I'll do a web search for `Cigna Q2 2026 earnings Evernorth segment profit margin`.

Let's fetch the Cigna Q2 2026 press release or Stocktitan 8-K to see the segment numbers. I'll search for `https://newsroom.thecignagroup.com/2026-07-30-The-Cigna-Group-Reports-Strong-Second-Quarter-2026-Results,-Raises-2026-Outlook` using `web_fetch`. This will give us the exact numbers from Cigna's Q2 2026 results.

This is also incredibly rich. Let's look at Cigna's Q2 2026 numbers: - Total revenues: $71.668 billion (up 7% from $67.178 billion in Q2 2025). - Evernorth Health Services segment (PBM + Specialty): - Adjusted Revenues: $61.468 billion (up 6% from $57.825 billion in Q2 2025). - Pharmacy Benefit Services (PBS) revenue: $34.496 billion (up 8% from $31.954 billion in Q2 2025). - Specialty and Care Services revenue: $26.972 billion (up 4% from $25.871 billion in Q2 2025). - Adjusted Income from Operations, Pre-Tax: $1.663 billion (down slightly from $1.696 billion in Q2 2025). - Pharmacy Benefit Services (PBS) pre-tax adjusted income: $609 million (down 27% from $833 million in Q2 2025). This matches the Finsee analysis: "Evernorth grew top-line revenue by 6%, but total pre-tax profits fell 2%. The culprit is a 27% YoY collapse in PBS income..." - Specialty and Care Services pre-tax adjusted income: $1.054 billion (up 22% from $863 million in Q2 2025). - Cigna Healthcare (Insurance) segment: - Adjusted Revenues: $11.728 billion (up 9% from $10.754 billion in Q2 2025). - Adjusted Income from Operations, Pre-Tax: $1.276 billion (up 17% from $1.094 billion in Q2 2025). - Pre-tax margin: 10.9% (up from 10.2% in Q2 2025). - The 2026 full-year expectation for Cigna Healthcare MCR is 83.7% to 84.7%. Wait! Let's examine this carefully. For Cigna: - Evernorth (PBM + Specialty) has revenues of $61.468 billion and pre-tax earnings of $1.663 billion. That's a 2.7% margin. - Cigna Healthcare (Insurance) has revenues of $11.728 billion and pre-tax earnings of $1.276 billion. That's a 10.9% margin. - In absolute terms, Evernorth generated $1.663 billion in pre-tax profits while Cigna Healthcare generated $1.276 billion. This means Evernorth represents 56.6% of Cigna's segment profits ($1.663B out of $2.939B total segment pre-tax profits). - Even though the insurance margin is higher (10.9% vs. 2.7%), the sheer scale of the PBM and specialty pharmacy business means it generates more than half of the company's operating profits. - And look at the shift within Evernorth: PBS (traditional PBM) pre-tax income dropped from $833 million to $609 million (a 27% decline), while Specialty and Care Services rose from $863 million to $1.054 billion (a 22% increase). This shows a critical shift in the profit engine: traditional PBM margins are under severe pressure, but specialty pharmacy/care services are booming and offsetting the decline. Let's do a search on CVS Health's Q2 2026 results to see how Aetna (insurance) is performing vs Caremark (PBM) vs Retail. Let's search for `CVS Health Q2 2026 earnings segment income Caremark Aetna`.

Let's fetch the CVS Health Q2 2026 press release or Stocktitan 8-K. The URL `https://investors.cvshealth.com/news/news-details/2026/CVS-HEALTH-CORPORATION-REPORTS-STRONG-SECOND-QUARTER-2026-RESULTS-AND-RAISES-FULL-YEAR-2026-GUIDANCE/default.aspx` is likely very detailed. Let's do a `web_fetch` on it. Wait, the domain is `investors.cvshealth.com`. Let's try to fetch that or search for a more accessible page first. Let's look at `https://www.cvshealth.com/news/company-news/cvs-health-corporation-reports-strong-second-quarter-2026-results-and-raises-full-year-2026-guidance.html.html` or search for the exact segment numbers. Let's search `CVS Health Q2 2026 segment operating income "Health Care Benefits" "Health Services"`.

Let's fetch the Stocktitan CVS Health 8-K filing at `https://www.stocktitan.net/sec-filings/CVS/8-k-cvs-health-corp-reports-material-event-f0307ac97161.html` to read the exact segment details. This will help us break down how CVS actually earns its profits across Health Care Benefits (Aetna), Health Services (Caremark PBM + specialty), and Pharmacy & Consumer Wellness (retail).

This is awesome. We have the exact Q2 2026 segment numbers for CVS Health: - Total Revenues: $106.096 billion (up 7.3% from $98.915 billion in Q2 2025). - Health Care Benefits (Aetna): - Total Revenues: $37.538 billion (up 3.5% from $36.258 billion in Q2 2025). - Premium Revenues: $35.119 billion (up 2.7% from $34.184 billion). - Government Premium: $28.494 billion (up 9.9% from $25.930 billion). - Commercial Premium: $6.625 billion (down 19.7% from $8.254 billion). This reflects the exit of the individual exchange business in 2026. - Medical Benefit Ratio (MBR): 87.4% (improved from 89.9% in Q2 2025). - GAAP Operating Income: $2.191 billion (up 118.7% from $1.002 billion). - Adjusted Operating Income: $2.426 billion (up 85.5% from $1.308 billion). - Health Services (Caremark PBM + Specialty + Care Delivery): - Total Revenues: $51.795 billion (up 11.5% from $46.453 billion in Q2 2025). - GAAP Operating Income: $1.603 billion (up 45.5% from $1.102 billion). - Adjusted Operating Income: $1.733 billion (up 10.0% from $1.575 billion). - Pharmacy & Consumer Wellness (Retail + Infusion): - Total Revenues: $33.816 billion (up 0.7% from $33.581 billion in Q2 2025). - GAAP Operating Income: $1.411 billion (up 91.7% from $736 million). - Adjusted Operating Income: $1.475 billion (up 10.2% from $1.338 billion). Let's do some math on where CVS Health's profits actually come from: - Total Segment Adjusted Operating Income (excluding Corporate/Other): - Health Care Benefits (Aetna): $2.426 billion (43.1% of total segment profits). - Health Services (Caremark PBM + Specialty): $1.733 billion (30.8% of total segment profits). - Pharmacy & Consumer Wellness (Retail): $1.475 billion (26.2% of total segment profits). - Total segment profits: $2.426B + $1.733B + $1.475B = $5.634 billion. - This is a remarkable recovery for Aetna (Health Care Benefits), which was severely depressed in 2025. In Q2 2025, Aetna's adjusted operating income was $1.308 billion (compared to Caremark's $1.575 billion and Retail's $1.338 billion). - Let's look at the margins: - Health Care Benefits (Aetna) Adjusted Operating Margin: $2.426B / $37.538B = 6.46% (up from 3.61% in Q2 2025). - Health Services (Caremark) Adjusted Operating Margin: $1.733B / $51.795B = 3.35% (down slightly from 3.39% in Q2 2025). - Pharmacy & Consumer Wellness (Retail) Adjusted Operating Margin: $1.475B / $33.816B = 4.36% (up from 3.98% in Q2 2025). Let's look at Humana (HUM). Humana is primarily a Medicare Advantage player. Let's do a search on Humana's Q2 2026 earnings, segment margins, and MCR. Let's search for `Humana Q2 2026 earnings segment income Medicare Advantage MCR`.

Let's fetch the Stocktitan Humana 8-K filing at `https://www.stocktitan.net/sec-filings/HUM/8-k-humana-inc-reports-material-event-9dea16857d3f.html` to read the exact segment numbers. This will show us how Humana's Insurance segment (called Insurance or Benefits) is performing and where CenterWell (their health services/care delivery segment, which includes primary care, home care, and pharmacy) fits in. Let's do a `web_fetch`.

This is incredibly helpful! We have the exact segment numbers for Humana: - Total Revenues: $40.867 billion (up 26.2% from $32.388 billion in Q2 2025). - Insurance Segment (Medicare Advantage, PDP, Medicaid, Commercial): - Total Revenues: $39.140 billion (up 25.9% from $31.094 billion in Q2 2025). - Premium Revenues breakdown: - Individual Medicare Advantage: $28.875 billion (up 26.8% from $22.764 billion). - Group Medicare Advantage: $2.851 billion (up 26.1% from $2.260 billion). - Medicare stand-alone PDP: $2.995 billion (up 74.0% from $1.721 billion). - State-based contracts and other (Medicaid etc.): $3.501 billion (up 1.2% from $3.460 billion). - Specialty benefits: $268 million (up 8.9% from $246 million). - Medicare Supplement: $344 million (up 29.8% from $265 million). - GAAP Operating Income: $820 million (up 7.0% from $766 million in Q2 2025). - Adjusted Operating Income: $824 million (up 7.0% from $770 million). - GAAP Benefit Ratio: 91.2% (up from 89.9% in Q2 2025). - GAAP Operating Cost Ratio: 7.1% (down from 8.3% in Q2 2025). - CenterWell Segment (Healthcare Delivery - Primary Care, Home, Pharmacy): - Total Revenues: $6.790 billion (up 22.6% from $5.537 billion in Q2 2025). - Services revenue breakdown: - Primary care: $2.008 billion (up 35.8% from $1.479 billion). - Pharmacy solutions: $3.793 billion (up 21.0% from $3.135 billion). - Home solutions: $989 million (up 7.2% from $923 million). - GAAP Operating Income: $466 million (up 35.5% from $344 million in Q2 2025). - Adjusted Operating Income (adding back depreciation/amortization of $48M): $514 million (up 27.2% from $404 million). - GAAP Operating Cost Ratio: 92.4% (down from 92.7% in Q2 2025). Let's do some math on Humana's segment profits: - Total Segment Operating Income: - Insurance: $820 million (63.8% of total segment profits). - CenterWell: $466 million (36.2% of total segment profits). - Total segment operating income: $820M + $466M = $1.286 billion. - Notice that CenterWell is a massive profit contributor for Humana. It represents 36.2% of Humana's segment profits, even though its revenue is only 16.6% of Humana's total gross revenues ($6.790B out of $40.867B). - Let's look at the margins: - Insurance Segment Operating Margin: $820M / $39.140B = 2.10% (down from 2.46% in Q2 2025). - CenterWell Segment Operating Margin: $466M / $6.790B = 6.86% (up from 6.21% in Q2 2025). - This is a perfect illustration of the core thesis: the insurance margin is extremely low (2.10%), and the profit engine of vertical integration (CenterWell) operates at a much higher margin (6.86%). Even with Medicare Advantage pricing and Star Ratings pressures (which drove the Insurance segment margin down), CenterWell's strong growth (Primary Care patients served grew 44.6% YoY to 622,000 across 398 centers) helped offset the Insurance headwinds. Let's do a search on Centene's Q2 2026 earnings to see their segment numbers. Centene (CNC) is primarily a Medicaid and ACA Individual Marketplace player. Let's search for `Centene Q2 2026 earnings segment income Medicaid Marketplace MCR`.

Let's fetch the Centene Q2 2026 press release or Stocktitan 8-K. The URL `https://investors.centene.com/2026-07-28-CENTENE-CORPORATION-REPORTS-SECOND-QUARTER-2026-RESULTS` is very relevant. Let's do a `web_fetch` on it. Let's find the exact numbers and quotes from Centene's Q2 2026 results. This will help us understand their Medicaid HBR (health benefits ratio, i.e., MLR) and Marketplace margins.

Let's analyze Centene's Q2 2026 earnings results: - Total revenues: $53.579 billion (vs. $51.520 billion in Q2 2025). - Premium and service revenues: $44.375 billion (up 4% from $42.467 billion in Q2 2025). - Medicaid: $22.766 billion (up 5% from $21.723 billion). - Commercial: $9.356 billion (down 7% from $10.070 billion). This is driven by lower Marketplace membership (3.49 million vs. 5.86 million in Q2 2025). - Medicare: $11.057 billion (up 17% from $9.450 billion). - Health benefits ratio (HBR): 89.6% (down from 93.0% in Q2 2025). - Let's look at the HBR by line of business: - Medicaid: 93.9% (in-line with expectations). - Medicare: 89.5% (down from 94.2% in Q2 2025). - Commercial (Marketplace): 79.2% (demonstrating significant improvement). - GAAP Diluted EPS: $2.19. - Adjusted Diluted EPS: $2.51. - Cash flow from operations: $3.590 billion. - Days in claims payable (DCP): 47 days. Wait, let's examine Centene's Marketplace membership drop: - Marketplace membership fell from 5.86 million at June 30, 2025 to 3.49 million at June 30, 2026. This is a massive contraction. - But look at the profitability of the Commercial segment: the HBR improved to 79.2% in Q2 2026. - The 10-Q press release notes: "The consolidated HBR benefited from a lower Marketplace HBR resulting from improved pricing and risk transfer reflecting the acuity of the Marketplace membership." - This represents a classic "price over volume" strategy. Centene shed higher-risk, unprofitable members (contracting from 5.86 million to 3.49 million) while drastically improving their pricing and risk-adjustment profiles, which resulted in a massive margin expansion in their remaining Marketplace business. This explains how their earnings beat expectations so significantly (Adjusted EPS of $2.51 vs. $0.89 est). Let's check the open threads and watches to see if we can resolve any. - Open Threads/Watches: 1. `UnitedHealth Group Prior Authorization Volume Reduction Target`: fire date is Dec 31, 2026. This is forward-looking. 2. `Elevance Health State-Level Medicaid Market Exits`: ongoing watch. 3. `Federal Court Ruling on Tennessee Fair RX Act Lawsuits`: one-shot. 4. `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law`: one-shot. 5. `Congress Progress on Patients Before Monopolies Act`: ongoing. 6. `CMS Star Ratings October 2026 Announcement`: fire date is Oct 15, 2026. Wait, let's look at Elevance Health's Q2 2026 results. Let's do a search on Elevance Health's Q2 2026 results, Medicaid exits, and Star Ratings bonus claim. Let's search `Elevance Health Q2 2026 earnings segment income Medicaid Star Ratings`.

Let's fetch the Elevance Health Q2 2026 Stocktitan 8-K filing at `https://www.stocktitan.net/sec-filings/ELV/8-k-elevance-health-inc-reports-material-event-03ce1655158e.html` to understand their exact segment performance: Health Benefits (insurance) vs. Carelon (services/vertical integration), and any comments on Medicaid rates and exits. Let's do a `web_fetch`.

This is extremely detailed and helpful. Let's analyze Elevance Health's Q2 2026 results: - Total Operating Revenue: $49.826 billion (up 0.8% from $49.421 billion in Q2 2025). - Health Benefits (Insurance): - Operating Revenue: $42.720 billion (up 2.7% from $41.582 billion in Q2 2025). - Revenue Details: - Commercial: $13.561 billion (up 8.9% from $12.453 billion). - Individual: $2.720 billion (up 16.8% from $2.328 billion). - Medicare: $10.962 billion (down 4.2% from $11.446 billion). - Medicaid: $14.444 billion (up 3.8% from $13.911 billion). - Federal Employee Program: $3.753 billion (down 0.5% from $3.772 billion). - Operating Gain: $896 million (down 42.6% from $1.560 billion in Q2 2025). - Operating Margin: 2.1% (down from 3.8% in Q2 2025). - CarelonRx (PBM): - Operating Revenue: $11.250 billion (up 5.7% from $10.643 billion in Q2 2025). - Operating Gain: $582 million (up 8.6% from $536 million). - Operating Margin: 5.2% (up from 5.0% in Q2 2025). - Carelon Services (Care Delivery + Healthcare services): - Operating Revenue: $7.975 billion (up 7.2% from $7.441 billion in Q2 2025). - Operating Gain: $366 million (down 8.5% from $400 million). - Operating Margin: 4.6% (down from 5.4% in Q2 2025). - Consolidated Carelon Segment (CarelonRx + Carelon Services): - Operating Gain: $582M + $366M = $948 million. - This is larger than the Health Benefits (Insurance) operating gain of $896 million! - Let's think about this: Carelon (vertical integration) represents 51.4% of Elevance's total reportable segments operating gain ($948M out of $1.844B total segment operating gain, excluding Corporate & Other). - This is a beautiful piece of evidence. For Elevance Health, more than half of its segment operating profits actually come from Carelon (their vertically integrated services and PBM arm), not from the core regulated health insurance business (Health Benefits), which is under severe Medicaid and Medicare Advantage cost pressure (operating margin down to 2.1%). Wait! Let's check the Medicaid exits for Elevance Health. - The watch description says: "Track additional state-level Medicaid market exits by Elevance Health (ELV) over the next 12 to 18 months, following its exit from the Washington D.C. market effective August 1, 2026. Multiple exits would signal a structural retreat from government-sponsored risk." - Let's check if there are any news of further Medicaid exits by Elevance Health. I'll search `Elevance Health Medicaid market exit 2026` or `Elevance Health exit Medicaid state`.

This is extremely useful. Let's look at the Medicaid situation for Elevance: - Elevance is exiting the Washington, D.C. Medicaid market effective August 1, 2026. - The company plans to exit other state Medicaid markets over the next 12 to 18 months due to unsustainable performance. - Mark Kaye (CFO) noted that Elevance's Medicaid operating margin is projected to be negative 1.75% for full-year 2026. This represents a severe mismatch between state reimbursement rates and member medical acuity after the post-pandemic "unwinding" (where healthier enrollees were removed from Medicaid, leaving a higher-acuity, more expensive pool). - In addition, there is a fascinating point about Elevance settling its Medicare Advantage risk adjustment data dispute with the CMS: - "The CMS came close to pausing enrollment in Elevance’s MA plans over the matter, but backed off after Elevance took actions to come into compliance, including refunding the government more than $342 million in May." - "The settlement was not as steep as it could have been: Elevance had estimated its exposure was likely around $935 million but could be as high as $1.5 billion." - Wait, let's look at their Q2 8-K details: "Corporate & Other operating gain... also included $935 million for the Company's current best estimate of the identified potential exposure for certain historical Medicare Advantage risk adjustment data related to the CMS notice to the Company dated February 27, 2026." So they took a $935 million charge, but settled for less or are in the process of finalizing it. Wait, let's look at the watches again: - `Elevance Health State-Level Medicaid Market Exits`: This ongoing watch tracks Elevance's state-level Medicaid exits. We can record a watch event because they confirmed they are exiting D.C. effective August 1, 2026, and explicitly stated on their Q2 2026 call (on July 15, 2026) that they "expect to exit additional Medicaid markets over the next 12 to 18 months where we do not see a path to sustainable performance." - Let's see if we have any other open threads. - Let's check the Arkansas or Tennessee PBM lawsuits. - `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` - `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` - Let's search for `Tennessee Fair RX Act Lawsuit PBM court ruling` or `Arkansas PBM pharmacy ownership Eighth Circuit appeal ruling`. Let's do a search on these.

Let's search for `Arkansas PBM pharmacy ownership Eighth Circuit appeal ruling 2026`. This will help us check if there has been a ruling on the Arkansas law.

Oh, the search budget is spent! No problem, we have an absolute wealth of primary evidence from the SEC filings and earnings releases of UnitedHealth (UNH), CVS Health (CVS), Cigna (CI), Humana (HUM), and Elevance Health (ELV), as well as Centene (CNC) for Q2 2026. This is perfect. Let's carefully review the findings we want to write or update: 1. **The Managed Care Profit Engine: Vertical Integration, Services, and the Regulated Margin Myth** (slug: `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins`) - We will update this note with the latest Q2 2026 segment data, showing that for Elevance, Carelon's operating gain of $948 million exceeded Health Benefits' gain of $896 million (making vertical integration 51.4% of segment profits). For Cigna, Evernorth's pre-tax adjusted income was $1.663 billion vs Cigna Healthcare's $1.276 billion (representing 56.6% of segment profits). For Humana, CenterWell generated $466 million in GAAP operating income (or $514M adjusted) vs $820 million for the Insurance segment (meaning CenterWell is 36.2% of segment operating income on only 16.6% of gross revenues, operating at a 6.86% margin vs. Insurance's 2.10% margin). For UnitedHealth, Optum consolidated operating earnings were $4.049 billion vs UnitedHealthcare's $3.942 billion. - This beautifully reinforces the core thesis: health insurers' massive profits do not come from the highly regulated, low-margin insurance business (which is currently under severe government funding and medical cost pressures), but from their vertically integrated pharmacy benefit managers, specialty pharmacies, and care delivery arms. 2. **UnitedHealth and Optum Vertical Integration & Strategic Medicare Advantage Contraction** (slug: `unitedhealth-optum-vertical-integration-medicare-advantage`) - We will update this note with UnitedHealth's Q2 2026 results. - Highlight the 9% contraction in Medicare Advantage and Medicaid membership at UnitedHealthcare due to "funding pressures, pricing and benefit actions, and state eligibility changes." - Show how Optum consolidated operating earnings grew 32% YoY to $4.05 billion, led by Optum Health ($1.19B, up 177% YoY with margin rebounding to 5.1% from 1.7% in Q2 2025) and Optum Insight ($1.369B, up 14% with a 25.3% operating margin), while UnitedHealthcare's operating earnings nearly doubled to $3.942 billion (operating margin of 4.6% vs 2.4% in Q2 2025) due to favorable prior-period reserve development ($1.25B favorable YTD) and pricing/benefit actions. 3. **CVS Health: Aetna's Government Recovery and Caremark PBM Dynamics** (slug: `cvs-health-aetna-government-recovery-caremark-pBM-dynamics`) - Wait, do we have an existing slug for CVS? Let's check the relevant prior findings: - `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` - `unitedhealth-optum-vertical-integration-medicare-advantage` - `regulatory-pbm-reform-vertical-integration-cracks` - `medicare-advantage-star-ratings-regulatory-litigation` - `centene-marketplace-risk-adjustment-wakely-catalyst` - We do not have a specific CVS slug, so we can mint a fresh, durable slug: `cvs-health-aetna-margin-recovery-caremark-pbm-segment-economics` or similar. Let's make it `cvs-health-aetna-margin-recovery-caremark-pbm-segment-economics`. - In this finding, we will detail CVS Health's Q2 2026 results. - Total revenues of $106.1 billion. - Health Care Benefits (Aetna) adjusted operating income jumped 85.5% to $2.426 billion with MBR improving to 87.4% (from 89.9% in Q2 2025), reflecting execution of its margin recovery plan, improved Government business performance, and the absence of a $471M premium deficiency reserve recorded in Q2 2025. - Health Services (Caremark PBM + specialty + clinics) adjusted operating income rose 10.0% to $1.733 billion, driven by improved purchasing economics, pharmacy drug mix, and Carelon-style delivery. - Pharmacy & Consumer Wellness (Retail) adjusted operating income rose 10.2% to $1.475 billion. - This illustrates Aetna's strong recovery, but also shows that Caremark and Retail combined still generated $3.208 billion (57% of total segment profits), anchoring CVS's earnings. 4. **Humana: CenterWell Vertical Integration and Medicare Advantage Star Ratings Headwinds** (slug: `humana-centerwell-vertical-integration-medicare-advantage-star-ratings`) - Humana is a critical case study of Medicare Advantage exposure. We can mint a fresh slug: `humana-centerwell-vertical-integration-medicare-advantage-star-ratings`. - In this finding, we will detail Humana's Q2 2026 results. - Consolidated revenues of $40.867 billion (up 26.2% YoY). - Diluted GAAP EPS of $5.73 and Adjusted EPS of $7.61 (up from $6.27 in Q2 2025). - However, Humana cut its FY 2026 GAAP EPS guidance from "at least $8.36" to "at least $6.52" due to the massive Bonus Year 2026 Star Ratings headwind (affecting Quality Bonus Payments). - This shows the extreme vulnerability of pure-play insurers to regulatory policy (Star Ratings). - On the other hand, CenterWell (their vertically integrated primary care, home, and pharmacy segment) grew revenues 22.6% to $6.790 billion, with GAAP operating income rising 35.5% to $466 million ($514M adjusted). CenterWell Senior Primary Care added 130,900 patients YTD (up 27%), serving 622,000 patients across 398 centers. CenterWell's operating margin of 6.86% far exceeded the Insurance segment's operating margin of 2.10% (under Star Ratings and medical cost trend pressures). 5. **Centene: Marketplace Risk Adjustment and the June Wakely Consulting Catalyst** (slug: `centene-marketplace-risk-adjustment-wakely-catalyst`) - We will update this note with Centene's Q2 2026 results. - Centene reported total revenues of $53.579 billion, with premium and service revenues of $44.375 billion. - Commercial (Marketplace) HBR dropped to 79.2% (a massive improvement in profitability) due to "improved pricing and risk transfer reflecting the acuity of the Marketplace membership." - This occurred even as Marketplace membership fell from 5.86 million in Q2 2025 to 3.49 million in Q2 2026. This demonstrates Centene's highly successful "price over volume" strategy in the ACA Individual Marketplace, shedding higher-risk membership and improving pricing power to drive massive margin expansion. 6. **Elevance Health: Medicaid Acuity Pressures and Carelon Segment Performance** (slug: `elevance-health-medicaid-acuity-pressures-carelon-segment-performance`) - We can mint a fresh slug: `elevance-health-medicaid-acuity-pressures-carelon-segment-performance`. - In this finding, we will detail Elevance's Q2 2026 results. - Total operating revenue of $49.826 billion. - Health Benefits (Insurance) operating gain fell 42.6% to $896 million, with operating margin compressing to 2.1% (down 170 bps). This was driven by expected elevated medical cost trends in Medicaid (Medicaid operating margin expected to be negative 1.75% for FY 2026). - This has prompted Elevance to exit Washington D.C.'s Medicaid market effective August 1, 2026, and plan further state-level Medicaid exits over the next 12 to 18 months. - In contrast, Carelon (CarelonRx + Carelon Services) generated $948 million in operating gain (CarelonRx: $582M, up 8.6%; Carelon Services: $366M), representing 51.4% of Elevance's segment operating profits. - This is a stark example of Carelon anchoring the enterprise while the core insurance business suffers from Medicaid post-unwinding acuity pressures. Let's check the watches we can record events for: - `Elevance Health State-Level Medicaid Market Exits`: - This watch's trigger is "Additional state Medicaid market exits by Elevance Health." - Event: Elevance confirmed exiting the Washington D.C. Medicaid market effective August 1, 2026, and explicitly stated on its Q2 2026 earnings call that it "expect[s] to exit additional Medicaid markets over the next 12 to 18 months where we do not see a path to sustainable performance." - We can call `record_event` on this watch. - Wait, does this resolve the watch? The watch description says "Multiple exits would signal a structural retreat from government-sponsored risk." Since this is an ongoing watch, we should set `resolves: false` because they are planning further exits over the next 12-18 months. Let's double-check if any other watches have fired. - `UnitedHealth Group Prior Authorization Volume Reduction Target`: fire date is Dec 31, 2026. - `Federal Court Ruling on Tennessee Fair RX Act Lawsuits`: no ruling yet, CVS filed in May 2026 and other PBMs filed in June 2026. - `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law`: wait! The search results showed: - "On June 29, 2026, in Flowers v. Caremark PCS Health, LLC, the Eighth Circuit U.S. Court of Appeals held that Arkansas regulations requiring..." - Wait, let's look at the Mintz article description: "On June 29, 2026, the Eighth Circuit Court of Appeals ruled in Flowers v. Caremark PCS Health, No. 25-3068, that a key element of an Arkansas..." - And the NFP article description: "On June 29, 2026, in Flowers v. Caremark PCS Health, LLC, the Eighth Circuit U.S. Court of Appeals held that Arkansas regulations requiring... ERISA preempts Arkansas PBM geographic coverage rules." - Wait, is this the Arkansas law prohibiting PBM ownership of pharmacies (Act 624)? Let's check the Duane Morris article description: "Arkansas' Act 624, would prohibit pharmacy benefits managers (PBMs) from owning or operate pharmacies in Arkansas, effective January 1, 2026. Federal Court Preliminarily Enjoins Arkansas' Ban on PBM Ownership..." - Wait, the Flowers case is about geographic coverage rules. The preliminary injunction blocking Act 624 was appealed to the 8th Circuit, but there is no final ruling yet on Act 624. So we shouldn't resolve the Arkansas PBM ownership watch yet. - `CMS Star Ratings October 2026 Announcement`: fire date is Oct 15, 2026. Let's write the updated and new notes! First, let's update `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins`. Let's read the prior note first using `read_notes` to see what is already in it, or we can just write it. Wait, the guidelines say: "Name a slug for the DURABLE SUBJECT it tracks... When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place — an upsert that snapshots a new revision." Let's call `read_notes` first to check the exact text of the existing notes. This is a very safe and accurate way to proceed.

This is amazing! We have several existing notes with highly relevant slugs: - `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins` - `unitedhealth-optum-vertical-integration-medicare-advantage` - `elevance-health-carelon-vertical-integration-internal-margins` - `regulatory-pbm-reform-vertical-integration-cracks` - `pbm-vertical-integration-state-ownership-restrictions` - `cigna-evernorth-pivot-commercial-focus` - `cvs-health-caremark-aetna-margin-recovery` - `humana-medicare-advantage-margin-compression` - `centene-medicaid-hbr-2027-policy-risk` - `centene-marketplace-risk-adjustment-wakely-catalyst` - `medicare-advantage-star-ratings-regulatory-litigation` This is perfect! We can reuse these exact slugs to update the notes with the latest Q2 2026 data. This maintains a beautiful living document. Let's update them one by one. Let's start with `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins`. This note explains the core thesis: that the public narrative about health insurers making massive profits on premiums is wrong, and that the profits are actually generated in vertically integrated services (PBMs, clinics, etc.) where margins are not restricted by MLR (regulated margins). Let's write this updated note. I will ground it in the Q2 2026 filings of UnitedHealth, CVS Health, Cigna, Humana, and Elevance Health. Wait, let's write the note body carefully. I will structure it with: - A clear title: `# The Managed Care Profit Engine: Vertical Integration, Services, and the Regulated Margin Myth` - Concrete evidence, quotes, and links to the `/markets` URLs of UNH, CVS, HUM, ELV, CI. - Let's include 1-2 verbatim quotes. - For example, Gail Boudreaux's quote on Carelon or Jim Rechtin's quote on CenterWell. - Or the quote from Elevance Health's Q2 2026 call: "At the end of the day, Medicaid participation has to make strategic and financial sense for us within our diversified portfolio... Where those conditions aren’t present, we’re going to take the disciplined action that we need to." - Or Jim Rechtin's quote: "When we get the clinical care right and run the business more efficiently, everything else follows—stronger earnings and better health and experiences for the people we serve." - Or CVS's CEO David Joyner: "Our CVS Health colleagues build trust every day in communities across our country... As our businesses work together to deliver a technology-powered care engagement experience, we continue to deliver strong performance." Let's write `us-health-insurers-profit-engine-vertical-integration-vs-regulated-margins`. I will use the `write_note` tool.

Now let's update the second note: `unitedhealth-optum-vertical-integration-medicare-advantage`. This note focuses specifically on UnitedHealth Group's vertical integration (Optum) and its strategic contraction in Medicare Advantage and Medicaid. Let's write this updated note. I will ground it in the Q2 2026 10-Q filing we fetched. Wait, let's review the key facts from UnitedHealth's Q2 2026 results: - Total revenues: $112.032 billion (flat). - Net earnings attributable to common shareholders: $5.484 billion (up 61% YoY from $3.406B). - Diluted EPS: $6.04 (up from $3.74). - Medical care ratio (MCR): 86.7% (improved from 89.4% in Q2 2025). This was aided by favorable prior-period reserve development ($1.25 billion favorable for the first six months of 2026 vs $320 million in H1 2025). - UnitedHealthcare medical membership contracted to 48.525 million (down 1.59 million from 50.115 million in Q2 2025). - Medicare Advantage and Medicaid membership each declined 9% YoY. This was due to pricing and benefit actions, county and market exits, and funding pressures. - Optum Health revenues declined 5% to $23.472 billion, but operating earnings jumped 177% to $1.190 billion (operating margin rebounded to 5.1% from 1.7% in Q2 2025). This reflects cost management, pricing actions, and reserve releases. - Optum consolidated operating earnings rose 32% to $4.049 billion. - UnitedHealthcare operating earnings rose 90% to $3.942 billion. Let's write `unitedhealth-optum-vertical-integration-medicare-advantage`. I will use the `write_note` tool.

Now let's update the third note: `elevance-health-carelon-vertical-integration-internal-margins` (slug: `elevance-health-carelon-vertical-integration-internal-margins`). Wait, the slug in `read_notes` is `elevance-health-carelon-vertical-integration-internal-margins`. Let's write this updated note with the Q2 2026 results we fetched. Let's review the key facts from Elevance's Q2 2026 results: - Operating revenue: $49.826 billion (up 0.8% YoY). - Shareholders' net income: $1.463 billion (down 16.1% YoY from $1.743B). - GAAP diluted EPS: $6.71. Adjusted diluted EPS: $7.45. - Benefit expense ratio (MBR): 89.7% (up 80 bps YoY). This was driven by expected elevated medical cost trends in Medicaid, partially offset by stronger Individual ACA results. - Medical membership: 44.949 million (down 1.5% YoY, and down 469,000 sequentially). - Health Benefits (Insurance) segment: - Operating Revenue: $42.720 billion (up 2.7% YoY). - Operating Gain: $896 million (down 42.6% YoY from $1.560B). - Operating Margin: 2.1% (down 170 bps). - Medicaid operating margin is expected to be negative 1.75% for FY 2026. - This has prompted the company to exit the Washington D.C. Medicaid market effective August 1, 2026, and plan further exits over the next 12 to 18 months. - Carelon Segment (CarelonRx + Carelon Services): - Operating Revenue: $19.2 billion (up 6% YoY). - Operating Gain: $948 million (CarelonRx: $582M, up 8.6%; Carelon Services: $366M, down 8.5%). - Carelon represented **51.4% of Elevance's total reportable segment operating profits**. - Corporate & Other included a $935 million accrual in H1 2026 for potential exposure related to a CMS notice on historical Medicare Advantage risk adjustment data (settled for a $342M refund in May 2026). Let's write `elevance-health-carelon-vertical-integration-internal-margins`. I will use the `write_note` tool.

Now let's update the fourth note: `cvs-health-caremark-aetna-margin-recovery` (slug: `cvs-health-caremark-aetna-margin-recovery`). Let's review the key facts from CVS Health's Q2 2026 results: - Total revenues: $106.096 billion (up 7.3% YoY). - GAAP diluted EPS: $2.31 (up from $0.80). Adjusted EPS: $2.58 (up from $1.81). - GAAP Operating Income: $4.703 billion (up 97.5% YoY from $2.381B). - Adjusted Operating Income: $5.157 billion (up 35.4% YoY from $3.808B). - Health Care Benefits (Aetna): - Total Revenues: $37.538 billion (up 3.5% YoY). - Premium Revenues: $35.119 billion. Government Premium: $28.494 billion (up 9.9%). Commercial Premium: $6.625 billion (down 19.7% due to individual exchange exit). - Medical Benefit Ratio (MBR): 87.4% (improved from 89.9% in Q2 2025). - Adjusted Operating Income: $2.426 billion (up 85.5% YoY from $1.308B), driven by Government business recovery and the absence of a $471M premium deficiency reserve recorded in Q2 2025. - Health Services (Caremark PBM + specialty + care delivery): - Total Revenues: $51.795 billion (up 11.5% YoY). - Adjusted Operating Income: $1.733 billion (up 10.0% YoY from $1.575B), driven by improved purchasing economics, pharmacy drug mix, and specialty pharmacy. - Pharmacy & Consumer Wellness (Retail): - Total Revenues: $33.816 billion (up 0.7% YoY). - Adjusted Operating Income: $1.475 billion (up 10.2% YoY from $1.338B), driven by core pharmacy strength and Rite Aid prescription file acquisitions. - Together, Health Services (PBM) and Retail generated $3.208 billion, representing **57% of total segment profits**, anchoring CVS's earnings. Let's write `cvs-health-caremark-aetna-margin-recovery`. I will use the `write_note` tool.

Now let's update the fifth note: `humana-medicare-advantage-margin-compression` (slug: `humana-medicare-advantage-margin-compression`). Wait, the existing note slug is `humana-medicare-advantage-margin-compression` but we can also use `humana-centerwell-vertical-integration-medicare-advantage-star-ratings` if we want, or keep the existing slug to update it in place. The guidelines say: "Name a slug for the DURABLE SUBJECT it tracks... When this cycle advances a subject you already have a finding for, call write_note with that SAME slug to revise it in place — an upsert that snapshots a new revision." So let's keep the existing slug: `humana-medicare-advantage-margin-compression` and update it in place with the Q2 2026 results. Let's review the key facts from Humana's Q2 2026 results: - Consolidated revenue: $40.867 billion (up 26.2% YoY). - GAAP EPS: $5.73. Adjusted EPS: $7.61 (up from $6.27 in Q2 2025). - However, Humana cut its FY 2026 GAAP EPS guidance from "at least $8.36" to "at least $6.52" due to the massive Bonus Year 2026 Star Ratings headwind. - Insurance Segment: - Total Revenues: $39.140 billion (up 25.9% YoY). - Individual Medicare Advantage premium revenues: $28.875 billion (up 26.8% YoY). - Group Medicare Advantage premium revenues: $2.851 billion (up 26.1%). - GAAP Benefit Ratio: 91.2% (up from 89.9% in Q2 2025). This reflects the Star Ratings headwind, higher-cost new members, and lower prior-period development ($53M favorable in Q2 2026 vs $161M in Q2 2025). - GAAP Operating Income: $820 million (operating margin of 2.10%). - CenterWell Segment (Vertical Integration): - Total Revenues: $6.790 billion (up 22.6% YoY). - Primary care revenues: $2.008 billion (up 35.8%). - Pharmacy solutions revenues: $3.793 billion (up 21.0%). - Home solutions revenues: $989 million (up 7.2%). - GAAP Operating Income: $466 million (operating margin of 6.86%). - Adjusted Operating Income: $514 million (adding back depreciation/amortization of $48M). - CenterWell Senior Primary Care added 130,900 patients YTD (up 27%), serving 622,000 patients across 398 centers (including de novo and wholly-owned). - This shows CenterWell's high-margin (6.86%) vertical integration acting as a critical buffer, while the pure-play Medicare Advantage insurance margin is highly compressed (2.10%) and exposed to regulatory (Star Ratings) shocks. Let's write `humana-medicare-advantage-margin-compression`. I will use the `write_note` tool.

Now let's update the sixth note: `centene-marketplace-risk-adjustment-wakely-catalyst` (slug: `centene-marketplace-risk-adjustment-wakely-catalyst`). Wait, let's review the key facts from Centene's Q2 2026 results: - Total revenues: $53.579 billion. - Premium and service revenues: $44.375 billion (up 4% YoY). - Medicaid: $22.766 billion (up 5% YoY). - Commercial: $9.356 billion (down 7% YoY). - Health benefits ratio (HBR): 89.6% (down from 93.0% in Q2 2025). - Commercial HBR: 79.2% (demonstrating significant year-over-year improvement in profitability). - Medicaid HBR: 93.9% (in-line with expectations). - Medicare HBR: 89.5% (down from 94.2% in Q2 2025). - Membership details: - Total Medicaid: 12.110 million (down from 12.819 million in Q2 2025). - Marketplace: 3.494 million (down from 5.862 million in Q2 2025). - The consolidated HBR benefited from improved pricing and risk transfer reflecting the acuity of the Marketplace membership, even as Marketplace membership fell from 5.86 million to 3.49 million. This demonstrates Centene's highly successful "price over volume" strategy in the ACA Individual Marketplace, shedding higher-risk membership and improving pricing power to drive massive margin expansion. - The company updated its 2026 Adjusted Diluted EPS guidance floor to greater than $4.80. Let's write `centene-marketplace-risk-adjustment-wakely-catalyst`. I will use the `write_note` tool.

This is fantastic! We have written and updated five critical notes that tell the full, grounded story of segment economics and vertical integration in US managed care, using Q2 2026 filings. Let's record the watch event for Elevance Health's Medicaid exits: - Thread ID: `019f7ea0-b32e-72b2-94d6-653dca807e67` - Title: `Elevance Health State-Level Medicaid Market Exits` - Description: "Track additional state-level Medicaid market exits by Elevance Health (ELV) over the next 12 to 18 months, following its exit from the Washington D.C. market effective August 1, 2026. Multiple exits would signal a structural retreat from government-sponsored risk." - Cycle ID: `topic-019e89d0-893e-7d00-a5cf-ca1051e66e9d-cycle-83cf097f-4b72-4ab6-b8ec-53646f51c932` - Summary: Elevance exited the Washington D.C. Medicaid market effective August 1, 2026, and confirmed it expects further state exits over the next 12-18 months. - Outcome: Confirmed exit from Washington D.C. (affecting 250,000 members) and announced plans for additional exits due to a projected negative 1.75% Medicaid operating margin for full-year 2026. - Resolves: `false` (it's an ongoing watch, as further exits are expected over the next 12-18 months). - Salience: 4 (very high significance for the sector). Let's call `record_event`.

Excellent! The event has been recorded successfully. Wait, are there any other threads we can resolve? The open threads we listed are: 1. `UnitedHealth Group Prior Authorization Volume Reduction Target` (watch, fire_date: 2026-12-31T00:00:00Z) 2. `Elevance Health State-Level Medicaid Market Exits` (watch, ongoing, which we recorded an event for but kept open) 3. `Federal Court Ruling on Tennessee Fair RX Act Lawsuits` (watch, one_shot) 4. `Eighth Circuit Ruling on Arkansas PBM Vertical Integration Law` (watch, one_shot) 5. `Congress Progress on Patients Before Monopolies Act (PBM Act)` (watch, ongoing) 6. `CMS Star Ratings October 2026 Announcement` (watch, one_shot, fire_date: 2026-10-15T00:00:00Z) Since none of the other watches have fully resolved or fired yet, we will keep them open and active. We don't need to call `resolve_thread` or `record_thread` since we don't have new open questions that can't be registered as watches. Wait, is there any other watch we want to register? No, our existing set of watches is extremely comprehensive and covers: - PBM vertical integration legislative and judicial challenges (Tennessee, Arkansas, federal PBM Act). - Medicaid exits (Elevance). - Medicare Advantage Star Ratings (CMS October 2026 announcement). - Prior authorization volume reduction targets (UnitedHealth Group). This is a beautiful, cohesive research cycle that directly answers the user's brief. We have fetched the primary SEC filings and earnings releases for Q2 2026, extracted precise segment revenues, operating gains, margins, and membership numbers, and interpreted them in the context of the core thesis: that US health insurers' profits are heavily concentrated in vertically integrated services segments (Optum, Carelon, Evernorth, CenterWell, Caremark) rather than the highly regulated, low-margin insurance segments. We also analyzed Centene's highly successful "price over volume" strategy in the ACA Individual Marketplace. Let's call `finish_cycle` to complete this research cycle. This is the ONLY way to complete a cycle.

I have completed this research cycle, during which I updated several core notes with the newly reported Q2 2026 financial metrics and segment results for the major managed care organizations (MCOs). ### Summary of Key Findings 1. **The Segment Economics of Vertical Integration (Core Thesis):** Our updated analysis of Q2 2026 filings for UnitedHealth, CVS Health, Cigna, Humana, and Elevance Health strongly reinforces the thesis that these companies are increasingly services-and-pharmacy businesses with an attached insurance front-end. The highly regulated, low-margin insurance arms are under severe cyclical and policy-driven cost pressures, while vertically integrated services arms capture the bulk of the profits: * **Elevance Health (ELV):** The **Carelon** segment (services and PBM) generated **51.4% of Elevance's total reportable segment operating profits** ($948M out of $1.844B), while its core Health Benefits insurance segment operated at a compressed margin of just 2.1% due to Medicaid cost pressures. * **The Cigna Group (CI):** **Evernorth** (PBM and Specialty Care) generated **56.6% of Cigna's total segment profits** ($1.663B out of $2.939B), driven by a 22% YoY surge in Specialty and Care Services ($1.054B) which offset a 27% decline in traditional PBM margins. * **Humana Inc. (HUM):** **CenterWell** (primary care, home, and pharmacy) generated **36.2% of Humana's segment profits** ($466M GAAP), despite representing only 16.6% of gross revenues, operating at a 6.86% GAAP margin vs. a tiny 2.10% margin in the Insurance segment. * **UnitedHealth Group (UNH):** **Optum** consolidated operating earnings were **50.7% of UNH's total segment operating profits** ($4.049B out of $7.991B), with Optum Health's margin rebounding to 5.1% and Optum Insight maintaining a stellar 25.3% operating margin. 2. **Strategic Contraction in Medicare Advantage & Medicaid:** To protect their consolidated margins from multi-year rate cuts and post-pandemic eligibility "unwinding" acuity mismatches, major MCOs are aggressively shedding unprofitable members: * **UnitedHealthcare** consolidated MCR improved to 86.7% (aided by $1.25B in favorable prior-period reserve development H1 YTD), but its medical membership fell by 1.59 million members, including **9% contractions in both Medicare Advantage and Medicaid enrollees**. * **Elevance Health** is executing a disciplined Medicaid retreat. Following its exit from the Washington, D.C. Medicaid market effective August 1, 2026, the company expects a **negative 1.75% Medicaid operating margin for FY 2026** and plans further state-level exits over the next 12 to 18 months. * **Humana** cut its FY 2026 GAAP EPS guidance from "at least $8.36" to "at least $6.52" due to a massive Bonus Year 2026 Star Ratings revenue headwind, showing the extreme vulnerability of pure-play insurance enrollees to regulatory shocks. 3. **Centene's "Price Over Volume" ACA Turnaround:** * **Centene (CNC)** successfully executed a margin recovery strategy in the ACA Individual Marketplace. By adjusting pricing and shedding higher-risk membership, Centene's Marketplace enrollees fell 40.4% YoY (to 3.494 million), but its **Commercial HBR dropped to a highly profitable 79.2%**, driving an Adjusted EPS of $2.51 (vs. $0.89 est) and enabling a guidance floor lift to greater than $4.80. 4. **CVS Aetna's Government Recovery:** * **CVS Health (CVS)** saw Aetna's (Health Care Benefits) adjusted operating income jump 85.5% to $2.426 billion with MBR improving to 87.4%, reflecting execution of its margin recovery plan. However, Caremark PBM and Retail pharmacy operations still combined for 57% of CVS's total segment profits, anchoring the enterprise. ### Recorded Events * **Elevance Health State-Level Medicaid Market Exits (`019f7ea0-b32e-72b2-94d6-653dca807e67`):** Recorded the August 1, 2026 Washington D.C. Medicaid exit and the company's explicit guidance regarding further state exits over the next 12 to 18 months. This watch remains open and active to monitor subsequent exits.